Very recently, the landscape of advanced-HCC treatment has changed with the combination of atezolizumab (anti PD-L1) and bevacizumab (anti-VEGF), which has become the standard treatment [41]. This evidence concerns the gene CD274 and hepatocellular carcinoma.